Literature DB >> 22989513

Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses the development of experimental autoimmune encephalomyelitis in rats.

Naoko Niimi1, Kuniko Kohyama, Yoh Matsumoto.   

Abstract

Gene silencing with siRNAs is important as a therapeutic tool in autoimmune diseases. In this study, we administered siRNAs specific for cytokines that may be involved in pathogenesis of experimental autoimmune encephalomyelitis (EAE). siRNA specific for IL-23p19 (siRNA-IL-23) suppressed EAE almost completely, whereas siRNA-IL-17A did not modulate the clinical course. Flow cytometric analysis revealed that siRNA-IL-23 significantly reduced the proportion of both IFN-γ(+)IL-17(-) Th1 and IFN-γ(-)IL-17(+) Th17 cells in the spinal cord. Consistent with this finding, siRNA-IL-23 treatment downregulated IL-12, IL-17 and IL-23 mRNAs. These findings indicate that IL-23, but not IL-17, play an important role in the development of EAE.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989513     DOI: 10.1016/j.jneuroim.2012.08.015

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats.

Authors:  Haiyan Xu; Min Cai; Xuedong Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-05       Impact factor: 3.117

2.  Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway.

Authors:  Junling Yang; Jinghong Kou; Jeong-Eun Lim; Robert Lalonde; Ken-Ichiro Fukuchi
Journal:  Brain Behav Immun       Date:  2015-11-10       Impact factor: 7.217

3.  Involvement of CX3CL1/CX3CR1 signaling in spinal long term potentiation.

Authors:  Chao Bian; Zhi-Qi Zhao; Yu-Qiu Zhang; Ning Lü
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.